


CrystEngComm

rsc.li/crystengcomm





ISSN 1466-8033

PAPER

Vânia André, Luis G. Alves *et al.*
Novel cyclam multicomponent crystal forms: synthesis,
characterization and antimicrobial activity


Cite this: *CrystEngComm*, 2023, 25, 5787

Novel cyclam multicomponent crystal forms: synthesis, characterization and antimicrobial activity†

Rajaa Saied,^a Paula C. Alves,^{ab} Patrícia Rijo,^{cd}
Vânia André ^{*ab} and Luis G. Alves ^{*ab}

Novel multicomponent crystal forms were obtained from reactions of *trans*-disubstituted cyclam derivatives with flufenamic and salicylic acids. The reactions of $\text{H}_2(4\text{-CF}_3\text{PhCH}_2)_2\text{cyclam}$ with those acids led to the formation of salts of the formulae $[\text{H}_2(\text{H}_2(4\text{-CF}_3\text{PhCH}_2)_2\text{cyclam})](^3\text{-CF}_3\text{PhNHC}_6\text{H}_4\text{COO})_2$ and $[\text{H}_2(\text{H}_2(4\text{-CF}_3\text{PhCH}_2)_2\text{cyclam})](\text{HOC}_6\text{H}_4\text{COO})_2$, respectively. The reaction of $\text{H}_2(\text{PhCH}_2)_2\text{cyclam}$ with flufenamic acid led to the formation of the salt $[\text{H}_2(\text{H}_2(\text{PhCH}_2)_2\text{cyclam})](^3\text{-CF}_3\text{PhNHC}_6\text{H}_4\text{COO})_2$, whereas its reaction with salicylic acid afforded the ionic cocrystal $[\text{H}_2(\text{PhCH}_2)_2\text{cyclam}](\text{HOC}_6\text{H}_4\text{-COOH})_2 \cdot [\text{H}_2(\text{H}_2(\text{PhCH}_2)_2\text{cyclam})](\text{HOC}_6\text{H}_4\text{COO})_2$. The compounds obtained were fully characterized and tested against several yeasts as well as Gram-positive and Gram-negative bacterial strains. The results have shown that the new multicomponent forms display relevant antimicrobial activity when compared to their parent cyclam derivatives, highlighting the importance of exploring synergistic effects to unveil new and efficient antimicrobial agents.

Received 12th April 2023,
Accepted 1st July 2023

DOI: 10.1039/d3ce00354j

rsc.li/crystengcomm

Introduction

Infections are still responsible for significant mortality rates worldwide due to multidrug resistant bacteria that drastically reduce the options for effective antimicrobial treatments, having a massive negative social and economic global impact.¹ For several years, pharmaceutical companies diminished the investment in the research and development of novel antimicrobials, whose financial return is currently lower than that for any other drug or vaccine.² More recently, pharmaceutical companies are being encouraged to improve the antibiotic pipeline.^{3,4}

Considering the variety of bacterial resistance mechanisms, it is necessary to establish a multifaceted response.⁵ Two possible approaches may be undertaken: (i)

the development of entirely new compounds, a time-consuming and risky approach or (ii) the modification of compounds already approved as antimicrobials, the best approach when it comes to short-term solutions for the current shortage of antimicrobials.⁶

Macrocyclic polyamines can play a role in the quest for alternative antimicrobial agents,⁷ and thus they have received a great interest over the past years because of their chemical and biological properties. For example, cyclam derivatives, which were previously studied as antiviral drugs against HIV,⁸ are now being explored as a novel class of antimicrobials.^{9–12} Recently, Alves *et al.* have shown that *trans*-disubstituted cyclam derivatives and their Fe(III) and Cu(II) metal complexes have antibacterial^{13,14} and antifungal¹⁵ properties. These results, together with the fact that cyclams display a highly versatile backbone easily modifiable by the introduction of new chemical substituents at the amino groups, highlight these molecules as a potential new family of antimicrobial drugs.

The efficiency of these tetrazamacrocycles can be further increased by applying crystal engineering and supramolecular chemistry principles for the design of new multicomponent compounds towards improved physicochemical properties that strongly influence the bioavailability, manufacturability, stability and other performance characteristics of the drugs^{16–20} as well as their activity. Indeed, a multicomponent crystal form enclosing cyclam and paracetamol has already been disclosed.²¹

^a Centro de Química Estrutural, Institute of Molecular Sciences, Instituto Superior Técnico, Universidade de Lisboa, Av. Rovisco Pais 1, 1049-001 Lisboa, Portugal. E-mail: vaniandre@tecnico.ulisboa.pt, luis.g.alves@tecnico.ulisboa.pt

^b Associação do Instituto Superior Técnico para a Investigação e Desenvolvimento, Avenida António José de Almeida, no. 12, 1000-043 Lisboa, Portugal

^c Universidade Lusófona's Research Center for Biosciences and Health Technologies (CBIOS), Campo Grande 376, 1749-024 Lisboa, Portugal

^d Research Institute for Medicines (iMed. ULisboa), Faculty of Pharmacy, Universidade de Lisboa (UL), Av. Prof. Gama Pinto, 1649-003 Lisboa, Portugal

† Electronic supplementary information (ESI) available: NMR, FT-IR, PXRD, hydrogen bonding details and antimicrobial activity data. CCDC 2243135–2243138. Crystallographic data of compounds 3–6 were deposited at the Cambridge Crystallographic Data Centre. For ESI and crystallographic data in CIF or other electronic format see DOI: <https://doi.org/10.1039/d3ce00354j>



According to the nature of the co-former, multicomponent crystal forms may be classified as solvates, salts, molecular cocrystals (MCCs) or ionic cocrystals (ICCs).²² Multicomponent crystal forms of two cyclam derivatives with known antimicrobial properties with flufenamic and salicylic acids envisaging synergistic effects are reported herein. Flufenamic acid has analgesic, anti-inflammatory, and antipyretic properties,²³ while salicylic acid displays topical antibacterial properties.²⁴ The design, synthesis, and characterization of novel multicomponent crystal forms by different techniques are presented as well as the assessment of the antimicrobial activity of the final compounds.

Experimental section

Synthesis and characterization

H₂(PhCH₂)₂cyclam, **1**,²⁵ and H₂(⁴-CF₃PhCH₂)₂cyclam, **2**,²⁶ were prepared according to previously described procedures. All other reagents were purchased from Sigma and used without further purification.

[H₂{H₂(PhCH₂)₂cyclam}](³-CF₃PhNHC₆H₄COO)₂ (3). Flufenamic acid (0.17 g, 0.60 mmol) and H₂(PhCH₂)₂cyclam (0.12 g, 0.31 mmol) were dissolved in 20 mL of dimethylformamide, and the mixture was stirred for 1 h. Slow evaporation of the solvent at room temperature afforded crystalline **3**, from which single crystals were selected for single-crystal X-ray diffraction. ¹H NMR (D₂O/(CD₃)₂SO, 300.1 MHz, 296 K): δ (ppm) 7.93 (d, ³J_{H-H} = 8 Hz, 2H, ³-CF₃PhNHC₆H₄COO), 7.49–7.19 (overlapping, 22H total, 10H, PhCH₂N, 8H, ³-CF₃PhNHC₆H₄COO and 4H, ³-CF₃PhNHC₆H₄COO), 6.80 (t, ³J_{H-H} = 7 Hz, 2H, ³-CF₃PhNHC₆H₄COO), 3.69 (s, 4H, PhCH₂-N), 2.97 (m, 4H [C2]CH₂N), 2.88 (m, 4H, [C3]CH₂N), 2.58 (m, 4H [C2]CH₂N), 2.47 (m, 4H, [C3]CH₂N), 1.79 (m, 4H, CH₂CH₂-CH₂). ¹³C{¹H} NMR (D₂O/(CD₃)₂SO, 75.5 MHz, 296 K): δ (ppm) 170.7 (C=O), 144.5 (C_{Ar}), 143.3 (C_{Ar}), 136.6 (C_{Ar}), 132.2 (C_{Ar}), 131.7 (C_{Ar}), 130.6 (C_{Ar}), 130.3 (q, ²J_{C-F} = 32 Hz, C_{Ar}), 129.9 (C_{Ar}), 128.3 (C_{Ar}), 127.4 (C_{Ar}), 124.3 (q, ¹J_{C-F} = 232 Hz, CF₃), 122.1 (C_{Ar}), 120.8 (C_{Ar}), 118.7 (C_{Ar}), 117.1 (q, ³J_{C-F} = 4 Hz, C_{Ar}), 114.6 (C_{Ar}), 114.4 (q, ³J_{C-F} = 4 Hz, C_{Ar}), 57.2 (PhCH₂-N), 49.8 ([C2]CH₂N), 48.6 ([C3]CH₂N), 46.5 ([C3]CH₂N), 45.6 ([C2]CH₂N), 23.5 (CH₂CH₂CH₂). ¹⁹F NMR (D₂O/(CD₃)₂SO, 282.4 MHz, 296 K): δ (ppm) -61.3 (CF₃). Anal. calcd for C₅₂H₅₆F₆N₆O₄: C, 66.23; H, 5.99; N, 8.91. Found: C, 65.91; H, 5.92; N, 8.87.

[H₂{H₂(⁴-CF₃PhCH₂)₂cyclam}](³-CF₃PhNHC₆H₄COO)₂ (4). Flufenamic acid (0.14 g, 0.50 mmol) and H₂(⁴-CF₃PhCH₂)₂cyclam (0.12 g, 0.24 mmol) were dissolved in 20 mL of dimethylformamide, and the mixture was stirred for 1 h. Slow evaporation of the solvent at room temperature afforded crystalline **4**, from which single-crystals were selected for single-crystal X-ray diffraction. ¹H NMR (D₂O/(CD₃)₂SO, 300.1 MHz, 296 K): δ (ppm) 7.93 (dd, ³J_{H-H} = 8 Hz, ⁴J_{H-H} = 1 Hz, 2H, ³-CF₃PhNHC₆H₄COO), 7.65 (d, ³J_{H-H} = 8 Hz, 4H, PhCH₂N), 7.54 (d, ³J_{H-H} = 8 Hz, 4H, PhCH₂N), 7.50–7.41 (overlapping, 4H total, ³-CF₃PhNHC₆H₄COO), 7.39 (s, 2H, ³-CF₃PhNHC₆H₄COO), 7.35–7.20 (overlapping, 6H total, ³-CF₃PhNHC₆H₄COO),

6.81 (t, ³J_{H-H} = 8 Hz, 2H, ³-CF₃PhNHC₆H₄COO), 3.75 (s, 4H, PhCH₂N), 2.95 (m, 4H [C2]CH₂N), 2.85 (m, 4H, [C3]CH₂N), 2.58 (m, 4H [C2]CH₂N), 2.47 (m, 4H, [C3]CH₂N), 1.79 (m, 4H, CH₂CH₂CH₂). ¹³C{¹H} NMR (D₂O/(CD₃)₂SO, 75.5 MHz, 296 K): δ (ppm) 170.5 (C=O), 144.6 (C_{Ar}), 143.1 (C_{Ar}), 141.9 (C_{Ar}), 132.1 (2xC_{Ar}), 130.6 (C_{Ar}), 130.4 (C_{Ar}), 130.3 (q, ²J_{C-F} = 33 Hz, C_{Ar}), 127.9 (q, ²J_{C-F} = 32 Hz, C_{Ar}), 125.1 (q, ³J_{C-F} = 4 Hz, 2xC_{Ar}), 124.4 (q, ¹J_{C-F} = 270 Hz, CF₃), 124.2 (q, ¹J_{C-F} = 284 Hz, CF₃), 122.3 (C_{Ar}), 120.0 (q, ³J_{C-F} = 4 Hz, C_{Ar}), 118.7 (C_{Ar}), 117.3 (q, ³J_{C-F} = 4 Hz, C_{Ar}), 114.6 (C_{Ar}), 56.9 (PhCH₂N), 50.0 ([C2]CH₂N), 48.4 ([C3]CH₂N), 46.5 ([C3]CH₂N), 45.7 ([C2]CH₂N), 23.6 (CH₂CH₂CH₂). ¹⁹F NMR (D₂O/(CD₃)₂SO, 282.4 MHz, 296 K): δ (ppm) -60.9 (CF₃), -61.4 (CF₃). Anal. calcd. for C₅₄H₅₄F₁₂N₆O₄·H₂O: C, 59.12; H, 5.15; N, 7.66. Found: C, 59.75; H, 4.40; N, 6.93.

[H₂(PhCH₂)₂cyclam](HOC₆H₄COOH)₂·[H₂{H₂(PhCH₂)₂cyclam}](HOC₆H₄COO)₂ (5). Salicylic acid (0.11 g, 0.76 mmol) and H₂(PhCH₂)₂cyclam (0.15 g, 0.38 mmol) were dissolved in 20 mL of dimethylformamide, and the mixture was stirred for 1 h. The solution evaporated to dryness under reduced pressure led to an oil that was redissolved in dimethylformamide and left to crystallize by slow evaporation of the solvent at room temperature, yielding crystals of **5** suitable for single-crystal X-ray diffraction. ¹H NMR (D₂O/(CD₃)₂SO, 300.1 MHz, 296 K): δ (ppm) 7.66 (d, ³J_{H-H} = 8 Hz, 2H, HOC₆H₄COO), 7.33–7.18 (overlapping, 14H total, 8H, PhCH₂N, 4H, HOC₆H₄COO and 2H, HOC₆H₄COO), 6.78 (overlapping, 4H total, 2H, PhCH₂N and 2H, HOC₆H₄COO), 3.43 (s, 4H, PhCH₂N), 3.16 (m, 4H, [C3]CH₂N), 3.10 (m, 4H, [C2]CH₂N), 2.60 (m, 4H, [C2]CH₂N), 2.52 (m, 4H, [C3]CH₂N), 1.85 (m, 4H, CH₂CH₂CH₂). ¹³C{¹H} NMR (D₂O/(CD₃)₂SO, 75.5 MHz, 296 K): δ (ppm) 175.3 (C=O), 161.5 (C_{Ar}), 135.4 (C_{Ar}), 135.2 (C_{Ar}), 131.9 (2xC_{Ar}), 130.4 (C_{Ar}), 129.8 (C_{Ar}), 120.6 (C_{Ar}), 119.4 (C_{Ar}), 117.7 (C_{Ar}), 56.6 (PhCH₂N), 53.2 ([C3]CH₂N), 51.8 ([C2]CH₂N), 49.9 ([C3]CH₂N), 46.3 ([C2]CH₂N), 22.9 (CH₂CH₂-CH₂). Anal. calcd for C₇₆H₉₆N₈O₁₂·H₂O: C, 68.55; H, 7.42; N, 8.41. Found: C, 68.44; H, 7.36; N, 8.39.

[H₂{H₂(⁴-CF₃PhCH₂)₂cyclam}](HOC₆H₄COO)₂ (6). Salicylic acid (0.08 g, 0.62 mmol) and H₂(⁴-CF₃PhCH₂)₂cyclam (0.15 g, 0.30 mmol) were dissolved in 20 mL of dimethylformamide, and the mixture was stirred for 1 h. The solution was evaporated to dryness under reduced pressure, resulting in an oil that was redissolved in dimethylformamide and left to crystallize by slow evaporation of the solvent at room temperature, yielding crystals of **6** suitable for single-crystal X-ray diffraction. ¹H NMR (D₂O/(CD₃)₂SO, 400.1 MHz, 296 K): δ (ppm) 7.77 (s, 2H, HOC₆H₄COO), 7.68–7.63 (overlapping, 6H total, 4H, PhCH₂N and 2H, HOC₆H₄COO), 7.41 (d, ³J_{H-H} = 6 Hz, 4H, PhCH₂N), 7.28 (t, 2H, HOC₆H₄COO), 6.78–6.74 (overlapping, 4H total, HOC₆H₄COO), 3.57 (s, 4H, PhCH₂N), 3.15 (overlapping, 8H total, 4H [C2]CH₂N and 4H [C3]CH₂N), 2.64 (m, 4H, [C2]CH₂N), 2.50 (m, 4H, [C3]CH₂N), 1.85 (m, 4H, CH₂CH₂CH₂). ¹³C{¹H} NMR (D₂O/(CD₃)₂SO, 100.1 MHz, 296 K): δ (ppm) δ (ppm) 174.5 (C=O), 161.5 (C_{Ar}), 140.3 (C_{Ar}), 135.2 (C_{Ar}), 132.2 (C_{Ar}), 131.7 (C_{Ar}), 126.9 (C_{Ar}), 126.8 (q, ³J_{C-F} = 3 Hz, C_{Ar}), 120.2 (C_{Ar}), 118.8 (C_{Ar}), 117.6 (C_{Ar}), 55.9



(PhCH₂N), 52.0 ([C3]CH₂N), 50.6 ([C2]CH₂N), 48.0 ([C2]CH₂N or [C3]CH₂N), 45.3 ([C2]CH₂N or [C3]CH₂N), 23.2 (CH₂CH₂-CH₂). CF₃ could not be identified due to the low intensity of the signal. ¹⁹F NMR (D₂O/(CD₃)₂SO), 376.5 MHz, 296 K): δ (ppm) -61.3 (s, CF₃). Anal. calcd for C₄₀H₄₆F₆N₄O₆·H₂O: C, 59.25; H, 5.97; N, 6.91. Found: C, 59.50; H, 5.65; N, 7.01.

Single-crystal X-ray diffraction (SCXRD) studies

Crystals of compounds 3–6 suitable for single-crystal X-ray diffraction studies were mounted on a loop with Fomblin® protective oil. Data were collected on a Bruker AXS-KAPPA D8 QUEST with graphite-monochromated radiation (Mo K α , λ = 0.71073 Å) at 293 K. An X-ray generator was operated at 50 kV and 30 mA and the APEX3 program monitored the data collection. Data were corrected for Lorentzian polarization and absorption effects using SAINT²⁷ and SADABS²⁸ programs. SHELXT 2014/4²⁹ was used for structure solution and SHELXL 2014/7³⁰ was used for full matrix least-squares refinement on F^2 . These two programs are included in the WINGX-Version 2014.1 program package.³¹ A full-matrix least-squares refinement was used for the non-hydrogen atoms with anisotropic thermal parameters. The hydrogens of carbons were inserted in idealized positions and allowed to refine in the parent carbon atom. The hydrogen atoms of OH, NH, NH₂⁺ and COOH moieties were located in the electron density map and the distances were restrained. Disorder in CF₃ moieties in 3, 4 and 6 has been modelled. Data quality of 5 precluded better refinement. MERCURY 2022.3.0³² was used for packing diagrams. PLATON³³ was used for determination of hydrogen bond interactions. Table 1 summarizes data collection and refinement details.

Crystallographic data of compounds 3–6 were deposited at the Cambridge Crystallographic Data Centre (CCDC 2243135–2243138).

General characterization

Powder X-ray diffraction (PXRD). Data were collected using a D8 Advance Bruker AXS θ -2 θ diffractometer equipped with a LYNXEYE-XE detector and a copper radiation source (Cu K α , λ = 1.5406 Å), operated at 40 kV and 40 mA. It was used to ascertain the bulk material purity of compounds 1–6 by comparing the calculated (from SCXRD data using MERCURY 2022.3.0 (ref. 32)) and experimental PXRD patterns. Data were collected in the 3–60° range in 2 θ , with a step size of 0.02°.

Nuclear magnetic resonance (NMR). NMR spectra were recorded on a Bruker AVANCE II 300 or 400 MHz spectrometer at 296 K. ¹H and ¹³C NMR spectra were referenced internally to residual solvent resonances and reported relative to tetramethylsilane (0 ppm). ¹⁹F NMR was referenced to external CF₃COOH (–76.55 ppm). 2D NMR experiments such as ¹H–¹³C{¹H} HSQC and ¹H–¹H COSY were performed to make all the assignments.

Fourier transform infrared (FT-IR) spectroscopy. FT-IR spectra were acquired on a Bruker ALPHA II ATR spectrometer with an individual diamond in the range of 400–3800 cm^{–1} with 4 cm^{–1} resolution.

Elemental analyses. Elemental analyses for carbon (C), hydrogen (H) and nitrogen (N) were performed on a Fisons CHNS/O analyzer (Carlo Erba Instruments EA-1108) at the IST Analyses Laboratory.

Melting point determination. The melting point of compounds 3–6 was determined by introducing a tiny

Table 1 Crystal data and structure refinement for compounds 3–6

	3	4	5	6
Empirical formula	C ₂₄ H ₃₈ N ₄ ·2(C ₁₄ H ₉ F ₃ NO ₂)	C ₂₆ H ₃₆ F ₆ N ₄ ·2(C ₁₄ H ₉ F ₃ NO ₂)	C ₂₄ H ₃₆ N ₄ ·C ₂₄ H ₃₈ N ₄ ·2(C ₇ H ₆ O ₃)·2(C ₇ H ₅ O ₃)	C ₂₆ H ₃₆ F ₆ N ₄ ·2(C ₇ H ₅ O ₃)
Formula weight	943.03	1079.03	1313.61	792.81
Crystal form, colour	Block, colourless	Block, colourless	Block, colourless	Block, colourless
Crystal size (mm)	0.20 × 0.20 × 0.20	0.20 × 0.20 × 0.10	0.20 × 0.20 × 0.20	0.40 × 0.40 × 0.16
Crystal system	Monoclinic	Monoclinic	Triclinic	Monoclinic
Space group	P2 ₁ /n	C2/c	P1	P2 ₁ /n
<i>a</i> , Å	15.790(1)	19.785(4)	10.881(2)	10.352(2)
<i>b</i> , Å	16.494(1)	18.079(4)	11.187(2)	18.345(4)
<i>c</i> , Å	19.737(2)	16.343(3)	16.516(3)	20.704(5)
α , °	90	90	70.972(6)	90
β , °	110.881(3)	115.629(7)	71.325(6)	93.095(9)
γ , °	90	90	85.357(7)	90
<i>Z</i>	4	4	1	4
<i>V</i> , Å ³	4802.7(7)	5270.9(19)	1799.9(5)	3926.4(15)
<i>T</i> , K	293	293	293	293
<i>D</i> _c , g cm ^{–3}	1.304	1.360	1.212	1.341
μ (Mo K α), mm ^{–1}	0.099	0.115	0.082	0.109
θ range (°)	2.052–24.999	2.253–24.994	1.978–24.999	2.929–25.000
Refl. collected	137596	49510	50632	114517
Independent refl.	8460	4621	6323	6805
<i>R</i> _{int}	0.1213	0.1440	0.1052	0.1180
<i>R</i> ₁ , ^a <i>wR</i> ₂ ^b [<i>I</i> ≥ 2 σ (<i>I</i>)]	0.0609, 0.1453	0.0887, 0.2464	0.0857, 0.2495	0.0605, 0.1438
GOF on <i>F</i> ²	1.055	1.064	1.088	1.055

^a $R_1 = \sum ||F_o| - |F_c|| / \sum |F_o|$. ^b $wR_2 = [\sum w(F_o^2 - F_c^2)^2 / \sum w(F_o^2)^2]^{1/2}$.



amount into a small capillary tube, and a melting point apparatus with a viewfinder was used to assess the following melting points: 169 °C for **3**, 178 °C for **4**, 194 °C for **5**, and 160 °C for **6**.

Antimicrobial activity assays. The antimicrobial activity of compounds **1–6** was tested against yeasts (*Candida albicans* ATCC 10231 and *Saccharomyces cerevisiae* ATCC 2601), Gram-negative bacteria (*Escherichia coli* ATCC 25922 and *Pseudomonas aeruginosa* ATCC 27853) and Gram-positive bacteria (*Staphylococcus aureus* (MRSA CIP 106760 and ATCC 25923), *Enterococcus faecalis* ATCC 29212 and *Mycobacterium smegmatis* ATCC 607). The minimum inhibitory concentration (MIC) values were determined by the microdilution method.^{34,35} Briefly, 100 μ L of Mueller-Hinton (for bacteria) or Sabouraud dextrose (for yeasts) liquid culture medium were added to all the 96 wells of the microtiter plates. Then, 100 μ L of the testing compounds at a concentration of 1 mg mL⁻¹ in dimethyl sulfoxide were added to the first well. Serial dilutions (1:2) were performed and 10 μ L of microbial inoculum was added to each well. The microtiter plates were incubated at 37 °C for 24 h and 48 h for bacteria and yeasts, respectively, and their growth was assessed through analysis of the optical density of cultures at 620 nm using a Thermo Scientific Multiskan FC (Loughborough, UK) microplate reader.

Results and discussion

Cyclam derivatives/flufenamic acid

Cyclam derivatives of the general formula H₂(^RPhCH₂)₂-cyclam, where R = H (**1**) and R = 4-CF₃ (**2**), reacted with two equivalents of flufenamic acid in DMF to yield salts of the formula [H₂{H₂(^RPhCH₂)₂cyclam}][³-CF₃PhNHC₆H₄COO]₂ (R = H, **3**, and R = 4-CF₃, **4**), as shown in Scheme 1.


Compounds **3** and **4** are dicationic salts that resulted from the protonation of the nitrogen atoms of the cyclam ring by the carboxylic acid moieties of flufenamic acid. The ¹H NMR spectra of both **3** and **4** reveal the presence of five signals integrating to four protons each that correspond to the CH₂ groups of the cyclam ring. The methylene protons of the pendant arms of the macrocycle show up as singlets at 3.69 ppm in **3** and at 3.75 ppm in **4**. In addition, the resonances due to the benzylic groups of cyclam and flufenamate anions

appear in the aromatic region of the spectra. The NH₂⁺ protons are not observed due to proton exchange in D₂O. The ¹³C{¹H} NMR spectra display five different resonances for the macrocycle backbone and one set of resonances that correspond to the benzylic moieties. The proton and carbon NMR spectra of **3** and **4** are in agreement with a C₂ symmetry in solution similarly to those obtained for other *trans*-disubstituted cyclam salts.³⁶ The ¹H and ¹³C{¹H} NMR spectra of compounds **3** and **4** are presented in Fig. S1 and S2,† respectively.

The IR spectra of **3** and **4** (Fig. S3 and S4,† respectively) reveal stretching vibrational bands assigned to the C–F bond stretching of –CF₃ groups between 1162 and 1065 cm⁻¹. The bands at 1326 cm⁻¹ in **3** and at 1327 cm⁻¹ in **4** assigned to the combination of ν_{C-C} , ν_{C-N} and ν_{N-H} modes are within the characteristic stretching vibrational bands of C–C and C–N modes (1400–1000 cm⁻¹).³⁷ The ν_{N-H} vibrational modes are also observed at higher frequencies but could be overlapped with the ν_{C-H} vibrational modes (1450–1300 cm⁻¹).³⁷ Hence, the bands ranging from 1453 to 1367 cm⁻¹ are assigned to the combination of ν_{N-H} and ν_{C-H} modes. Nevertheless, these bands are overlapped by the strong absorption stretching vibration bands at 1581 to 1367 cm⁻¹ assigned to $\nu_{C=O}$ and ν_{C-O} , respectively, of the flufenamate anions. The ν_{C-C} stretching (in-ring) bands observed at 1630 cm⁻¹ in **3** and at 1653 cm⁻¹ in **4** are assigned to the aromatic rings.

The structural elucidation of compounds **3** and **4** was confirmed from single-crystal X-ray diffraction data that allowed the structure determination of both compounds. The purity of both bulk samples was checked by powder X-ray diffraction data (Fig. S5 and S6,† respectively).

The asymmetric unit of **3** consists of two deprotonated flufenamic acid moieties and two halves of crystallographically independent protonated cyclam moieties residing on inversion centres (see Fig. 1). The determination of the salt nature of **3** arose from the confirmation of the deprotonation of the carboxylic acid group of flufenamic acid by the C–O distances (1.250(3), 1.258(4), 1.263(3) and 1.249(3)



Scheme 1 Synthetic route for the preparation of **3** and **4**.




Fig. 1 Asymmetric unit of **3**, representing two crystallographically independent flufenamate moieties and two independent protonated cyclam moieties residing on inversion centres (represented by the yellow dots). The full protonated cyclams are represented for better understanding and hydrogen atoms have been omitted for clarity.



Å) and the location of hydrogen atoms from the electron density maps revealing the protonation of the cyclam secondary amines. Thus, compound **3** is a dicationic salt with the presence of two NH_2^+ groups in the cyclam ring.

Flufenamate moieties assume antiparallel orientations in the overall packing, interacting almost perpendicularly with cyclam. Charge-assisted hydrogen bonds are established between the cyclam ring and flufenamate anions *via* several $\text{N}^+-\text{H}\cdots\text{O}_{\text{COO}^-}$ interactions (2.853(3), 3.151(3), 2.766(3), 2.752(3), and 2.759(3) Å), with each cyclam interacting only with a single type of crystallographically independent flufenamate, as shown in Fig. 2a. Apart from these intermolecular hydrogen bonds, there are also intramolecular bonds found in flufenamate between amines and carboxylate groups (2.652(3) and 2.617(4) Å) (see Fig. 2a). The list of the main hydrogen bonds found in compound **3** is presented in Table S1.† The combination of these interactions results in a supramolecular arrangement where it is possible to see that in a view along the *b* axis, the flufenamate–cyclam–flufenamate groups align along the *ac* diagonal (Fig. 2b) with alternate lines being formed by crystallographically independent entities.

The asymmetric unit of compound **4** is formed by half of a protonated cyclam molecule residing on an inversion center and one deprotonated flufenamic acid moiety (see Fig. 3). The C–O bond distances in the flufenamate (1.264(4) and 1.251(6) Å) indicate that these molecules have transferred the carboxylic protons to the secondary amines of cyclam, giving rise to flufenamate anions, as observed in the formation of **3**. Thus, compound **4** is also a dicationic salt with the presence of two NH_2^+ groups in the cyclam ring, confirmed by the electron density maps.




Fig. 2 (a) Detailed view of the hydrogen bonds established in **3** between each crystallographically independent cyclam and two crystallographically dependent flufenamic acid molecules, with intramolecular interactions represented in dark blue and non-contact hydrogen atoms omitted for clarity. (b) Supramolecular arrangement of **3** in a view along the *b* axis, with hydrogen atoms omitted for clarity.




Fig. 3 Asymmetric unit of **4**, with representation of the full protonated cyclam residing on an inversion center (represented by the yellow dot) for better understanding; hydrogen atoms have been omitted for clarity.

The interactions between the cyclam ring and flufenamate are established by $\text{N}^+-\text{H}\cdots\text{O}_{\text{COO}^-}$ charge-assisted hydrogen bonds (2.766(5), 2.754(5) and 3.223(5) Å), as shown in Fig. 4a. Apart from these intermolecular hydrogen bonds, there are also intramolecular bonds found in flufenamate between amines and carboxylate groups (2.653(5) Å) as well as within cyclam *via* a $\text{N}^+-\text{H}\cdots\text{N}$ (3.013(4) Å) hydrogen bond. A list of the main hydrogen bonds found in compound **4** is presented in Table S2.†

Regarding the supramolecular arrangement, it is possible to see that in a view along the *a* axis, each of the flufenamate–cyclam–flufenamate groups shown in Fig. 4b aligns along the *ac* diagonal. Alternate lines are formed by crystallographically independent groups.

Cyclam derivatives/salicylic acid

The cyclam derivative $\text{H}_2(\text{PhCH}_2)_2\text{cyclam}$, **1**, reacted with two equivalents of salicylic acid in DMF to yield an ionic cocrystal of the formula $[\text{H}_2(\text{PhCH}_2)_2\text{cyclam}][\text{HOC}_6\text{H}_4\text{COOH}]_2 \cdot [\text{H}_2\{\text{H}_2(\text{PhCH}_2)_2\text{cyclam}\}][\text{HOC}_6\text{H}_4\text{COO}]_2$, **5**. On the other hand, the reaction of $\text{H}_2(^{4-\text{CF}_3}\text{PhCH}_2)_2\text{cyclam}$, **2**, with two equivalents of salicylic acid in DMF afforded the salt $[\text{H}_2\{\text{H}_2(^{4-\text{CF}_3}\text{PhCH}_2)_2\text{cyclam}\}][\text{HOC}_6\text{H}_4\text{COO}]_2$, **6**. The synthetic route to obtain compounds **5** and **6** is shown in Scheme 2.

Compounds **5** and **6** can also be obtained using acetylsalicylic acid instead of salicylic acid as starting material. This result is attributed to the hydrolysis of





Fig. 4 (a) Detailed view of the hydrogen bonds established in **4**, with intramolecular interactions represented in dark blue and non-contact hydrogen atoms omitted for clarity. (b) Supramolecular arrangement of **4** in a view along the *a* axis, with hydrogen atoms omitted for clarity.





Scheme 2 Synthetic route for the preparation of **5** and **6**.

acetylsalicylic acid into salicylic acid in solution, as a similar behaviour has already been reported for similar systems.³⁸ The proton and carbon NMR spectra of **5** and **6** are similar to those obtained for compounds **3** and **4**. The similarity of the NMR spectra of the ionic cocrystal **5** with those obtained for the salts **3**, **4** and **6** might be due to the fact that in a D₂O/(CD₃)₂SO solution, hydrogen bonds between cations and anions are broken. Furthermore, the COOH, NH and NH₂⁺ protons cannot be distinguished due to proton/deuterium exchange with D₂O. The ¹H and ¹³C{¹H} NMR spectra of compounds **5** and **6** are shown in Fig. S7 and S8,† respectively.

The IR spectra of **5** and **6** (Fig. S9 and S10,† respectively) show bands at 1326 and 1324 cm⁻¹, respectively, which are assigned to the combination of ν_{C-C}, ν_{C-N} and ν_{N-H} modes. The ν_{N-H} vibrational modes are also observed at higher frequencies but could be overlapped with the ν_{C-H} vibrational modes (1450–1300 cm⁻¹).³⁷ Hence, the bands ranging from 1457 to 1381 cm⁻¹ are assigned to the combination of ν_{N-H} and ν_{C-H} modes. Nevertheless, these bands are overlapped by the strong absorption stretching vibration bands at 1595 to 1381 cm⁻¹ assigned to ν_{C=O} and ν_{C-O}, respectively, of the salicylate anions. The ν_{C-C} stretching (in-ring) bands observed at 1643 cm⁻¹ in both compounds are assigned to the aromatic rings. In the IR spectrum of **6**, stretching vibrational bands assigned to the C-F bond stretching of -CF₃ groups are observed between 1162 and 1066 cm⁻¹.

Crystals of **5** and **6** suitable for single-crystal X-ray diffraction were obtained from slow evaporation of a DMF solution after one week. Crystallographic and experimental details of data collection and crystal structure determination are presented in Table 1. The asymmetric unit of compound **5** is formed by one half of neutral cyclam with one salicylic acid moiety, and one half of protonated cyclam with a salicylate moiety. Both cyclams are placed on inversion centres as shown in Fig. 5. The C–O bond distances in salicylic acid are 1.185(9) and 1.282(8) Å and the C–O bond distances in the salicylate moiety are 1.264(5) and 1.246(7) Å, revealing the presence of both neutral and protonated parts, and thus the formation of an ionic cocrystal.




Fig. 5 Asymmetric unit of compound **5**, representing the neutral [H₂(PhCH₂)₂cyclam](HOC₆H₄COOH)₂ and the [H₂(H₂(PhCH₂)₂cyclam)]²⁺(HOC₆H₄COO)⁻₂ pairs in the asymmetric unit, depicting the relevant hydrogen atoms to depict the ICC character of form **5**, with both cyclams residing on inversion centers (represented by the yellow dots) being fully represented for better understanding. Hydrogen atoms have been omitted for clarity, except the ones determining the formation of an ICC.

Interactions within the neutral salicylic acid and cyclam are established *via* N–H⋯O_{COOH} and O–H_{COOH}⋯N hydrogen bonds (2.741(5) and 2.799(6) Å). These are replaced by two N⁺–H⋯O_{COO}⁻ charge-assisted hydrogen bonds (2.807(6) and 2.746(6) Å) in the ionic part.

Apart from these intermolecular interactions, there are also intramolecular bonds found in the salicylic acid moieties between the hydroxyl and the carboxylic acid/carboxylate groups (2.531(7) and 2.497(5) Å) (see Fig. 6a). The list of the main hydrogen bonds formed in compound **5** is presented in Table S3.†

Regarding the supramolecular arrangement, it is possible to see that in a view along the *b* axis, cyclam aligns in zigzag chains of alternate protonated and neutral cyclam **1**, leaving cages occupied by two salicylate anions and two neutral salicylic acid molecules (Fig. 6b).

The asymmetric unit of **6** consists of one protonated cyclam and two salicylate moieties, as shown in Fig. 7. The C–O bond distances (1.278(4) and 1.244(4); 1.271(4) and 1.256(4) Å) indicate that the carboxylic acid groups exchanged the proton with cyclam, giving rise to salicylate anions. The salt character of **6** is confirmed by the protonation of both of cyclam's NH groups.




Fig. 6 (a) Detailed view of the hydrogen bonds established in **5**, with intramolecular interactions represented in dark blue and non-contact hydrogen atoms omitted for clarity. (b) Supramolecular arrangement of **5** in a view along the *b* axis, with hydrogen atoms omitted for clarity.






Fig. 7 Asymmetric unit of **6**. Hydrogen atoms have been omitted for clarity.

The interactions between cyclam and salicylate moieties are established by $N^+-H\cdots O_{COO^-}$ charge-assisted hydrogen bonds (2.876(4), 3.179(3), 2.824(4), 2.845(4) and 2.792(4) Å). Apart from these, there are intramolecular bonds in both salicylates established between the hydroxyl and carboxylic groups (2.557(3) and 2.558(3) Å) and in cyclams between one of the protonated NH groups and one of the N-substituted (3.051(3) and 3.071(4) Å) (see Fig. 8a). A list of the main hydrogen bonds found in compound **6** is presented in Table S4†. The overall supramolecular arrangement of **6** is very similar to the packing of **5** with cyclam aligning in zigzag chains, forming cages that are occupied by both crystallographically independent salicylates, in a view along the *a* axis (Fig. 8b).

Biological assays

The minimum inhibitory concentration (MIC) values of compounds **1–6** were determined against a set of yeasts and Gram-positive and Gram-negative bacteria, revealing that the new multicomponent forms **3–6** display relevant antimicrobial activity when compared to their parent compounds **1** and **2** (Table S5† and Fig. 9).

Compound **3** presents lower MIC values for *E. faecalis*, *P. aeruginosa* and *S. cerevisiae* than compound **1**, but both compounds show similar antibacterial activity for *S. aureus*, *E. coli* and *C. albicans*. The highest MIC value detected for **3** is 40.63 $\mu\text{g mL}^{-1}$ for both *M. smegmatis* and methicillin-




Fig. 8 (a) Detailed view of the hydrogen bonds established in **6**, with intramolecular interactions represented in dark blue and non-contact hydrogen atoms omitted for clarity. (b) Supramolecular arrangement of **6** in a view along the *a* axis, with hydrogen atoms omitted for clarity.




Fig. 9 Minimum inhibitory concentration values (MIC, $\mu\text{g mL}^{-1}$) of compounds **3–6** and the corresponding starting materials for *Candida albicans* and *Saccharomyces cerevisiae* (yeasts), *Escherichia coli* and *Pseudomonas aeruginosa* (Gram-negative bacteria) and *Staphylococcus aureus*, *Enterococcus faecalis* and *Mycobacterium smegmatis* (Gram-positive bacteria) after 24 h for bacteria and 48 h for yeasts. DMSO was used as negative control, and nystatin, norfloxacin and vancomycin were used as positive controls for yeasts, Gram-negative bacteria and Gram-positive bacteria, respectively.

resistant *S. aureus* (MRSA), which represents a decreased activity compared to **1**, but when compared to flufenamic acid, **3** presents augmented antimycobacterial activity to *M. smegmatis*. Compound **4** displays lower or similar antimicrobial activity when compared to **2**. Moreover, **4** seems to be not selective, as it presents the same MIC value ($7.81 \mu\text{g mL}^{-1}$) for the set of tested bacteria. Comparing **3** and **4**, it can be noted that **4** is more active against *M. smegmatis* and MRSA and that both compounds show a similar impact on cultures of *E. faecalis*, *P. aeruginosa*, both *S. aureus* strains and *E. coli*. The antimicrobial activity of **5** to *P. aeruginosa* is higher than that of compound **1** but very similar for *M. smegmatis*, *E. coli* and MRSA. Compounds **6** and **2** present similar effects to *S. aureus* and *E. coli*. When compared to **5**, compound **6** is more active against all tested bacteria except *P. aeruginosa*, with **5** being more active against both yeasts. In addition, compounds **4** and **6** display MIC values against *M. smegmatis* very close to the control vancomycin. On the other hand, **3** and **5** are more active to *P. aeruginosa* and both yeasts. Compound **1** revealed to be a better antimycotic agent, showing lower MIC values for *C. albicans* and *S. cerevisiae*, while compound **2** displays higher antimicrobial activity against *M. smegmatis*, *P. aeruginosa*, *E. faecalis* and MRSA. Considering the microorganisms selected for this study, it is clear that the combined effect of the cyclams **1** and **2** with flufenamic acid, increases the antimicrobial activity, except against MRSA.

Conclusions

Novel flufenamic and salicylic acid–cyclam multicomponent crystal forms were synthesized and characterized. Structural characterization allowed concluding the formation of three salts (**3**, **4** and **6**) and an ionic cocrystal (**5**).



The antimicrobial activity of the novel forms 3–6 was compared with the activity of the starting compounds, revealing promising results. In an attempt to establish a trend in the efficiency of the tested compounds, it can be said that flufenamic acid is the most active compound against methicillin-resistant *S. aureus* (MRSA). Compound 1 is a better antimycotic agent, displaying lower MIC values for *C. albicans*, while compounds 2, 4 and 6 show higher activity against *M. smegmatis*. Compound 5 can strongly inhibit the growth of the tested Gram-negative bacteria, with compound 3 a good choice to battle *P. aeruginosa*.

Overall, these results highlight the benefits of the synergistic effects that can be established between active principal ingredients to produce new and efficient antimicrobial agents able to fight drug resistant bacteria like *S. aureus*, which are responsible for several nosocomial infections.

Author contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors acknowledge funding from Fundação para a Ciência e a Tecnologia (projects UIDB/00100/2020, UIDP/00100/2020, LA/P/0056/2020, UIDB/04567/2020 and UIDP/04567/2020 and PTDC/QUI-OUT/30988/2017), contracts under DL No. 57/2016 regulation, and CEECIND/00283/2018; FEDER, Portugal2020 and Lisboa2020 (project LISBOA-01-0145-FEDER-030988).

References

- 1 C. J. L. Murray, K. S. Ikuta, F. Sharara, L. Swetschinski, G. R. Aguilar, A. Gray, C. Han, C. Bisignano, P. Rao, E. Wool, S. C. Johnson, A. J. Browne, M. G. Chipeta, F. Fell, S. Hackett, G. Haines-Woodhouse, B. H. K. Hamadani, E. A. P. Kumaran, B. McManigal, R. Agarwal, S. Akech, S. Albertson, J. Amuasi, J. Andrews, A. Araykin, E. Ashley, F. Bailey, S. Baker, B. Basnyat, A. Bekker, R. Bender, A. Bethou, J. Bielicki, S. Boonkasidecha, J. Bukosia, C. Carnevali, C. Castañeda-Orjuela, V. Chansamouth, S. Chaurasia, S. Chiurciu, F. Chowdhury, A. J. Cook, B. Cooper, T. R. Cressey, E. Criollo-Mora, M. Cunningham, S. Barboe, N. P. J. Day, M. D. Luca, K. Dokova, A. Dramowski, S. J. Dunachie, T. Eckmanns, D. Eibach, A. Emami, N. Feasy, N. Fisher-Pearson, K. Forrest, D. Garrett, P. Gastmeier, A. Z. Giref, R. C. Greer, V. Gupta, S. Haller, A. Haselbeck, S. I. Hay, M. Holm, S. Hopkins, K. C. Iregbu, J. Jacobs, D. Jarovsky, F. Javanmardi, M. Khorana, N. Kissoon, E. Kobeissi, T. Kostyanov, F. Krapp, R. Krumkamp, A. Kumar, H. H. Kyu, C. Lim, D. Limmathurotsakul, M. J. Loftus, M. Lunn, J. Ma, T. Munera-Huertas, P. Musicha, M. M. Mussi-Pinhata, T. Nakamura, R. Nanayati, S. Nangia, P. Newton, C. Ngoun, A. Novotney, D. Nwakanma, C. W. Obiero, A. Olivas-Martinez, P. Oliaro, E. Ooko, E. Ortiz-Brizuela, A. Y. Peleg, C. Perrone, N. Plakkal, A. Ponce-de-Leon, M. Raad, T. Ramdin, T. Roberts, J. V. Robotham, A. Roca, K. E. Rudd, N. Russell, J. Schnall, J. A. G. Scott, M. Shivamallappa, J. Sifuentes-Osornio, N. Steenkeste, A. J. Stewardson, T. Stoeva, N. Tasak, A. Thaiprakong, G. Thwaites, C. Turner, P. Turner, H. R. van Doorn, S. Velaphi, A. Vongpradith, H. Vu, T. Walsh, S. Waner, T. Wangrangsimakul, T. Wozniak, P. Zheng, B. Sartorius, A. D. Lopez, A. Stergachis, C. Moore, C. Dolecek and M. Naghavi, *Lancet*, 2022, **399**, 629.
- 2 B. Plackett, *Nature*, 2020, **586**, S50.
- 3 C. Morel, O. Lindahl, S. Harbarth, M. de Kraker, S. Edwards and A. Hollis, *J. Antibiot.*, 2020, **73**, 421.
- 4 S. A. Hillier and I. A. Dutescu, *Infect. Drug Resist.*, 2021, **14**, 415.
- 5 S. A. Sousa, J. R. Feliciano, T. Pita, C. F. Soeiro, B. L. Mendes, L. G. Alves and J. H. Leitão, *Antibiotics*, 2021, **10**, 942.
- 6 T. T. Ashburn and K. B. Thor, *Nat. Rev. Drug Discovery*, 2004, **3**, 673.
- 7 X. Liang and P. J. Sadler, *Chem. Soc. Rev.*, 2004, **22**, 246.
- 8 G. J. Bridger, R. T. Skerlj, D. Thornton, S. Padmanabhan, S. A. Martellucci, G. W. Henson, M. J. Abrams, N. Yamamoto, K. De Vreeze, R. Pauwels and E. J. De Clercq, *Med. Chem.*, 1995, **38**, 366.
- 9 M. Spain, J. K.-H. Wong, G. Nagalingam, J. M. Batten, E. Hurtle, S. H. Oehlers, X. F. Jiang, H. E. Murage, J. T. Orford, P. Crisologo, J. A. Triccas, P. J. Rutledge and M. H. J. Todd, *Med. Chem.*, 2018, **61**, 3595.
- 10 T. J. Hubin, P. N.-A. Amoyaw, K. D. Roewe, N. C. Simpson, R. D. Maples, T. N. C. Freeman, A. N. Cain, J. G. Le, S. J. Archibald, S. I. Khan, B. L. Tekwani and M. O. F. Khan, *Bioorg. Med. Chem.*, 2014, **22**, 3239.
- 11 M. O. F. Khan, J. Keiser, P. N. A. Amoyaw, M. F. Hossain, M. Vargas, J. G. Le, N. C. Simpson, K. D. Roewe, T. N. C. Freeman, T. R. Hasley, R. D. Maples, S. J. Archibald and T. J. Hubin, *Antimicrob. Agents Chemother.*, 2016, **60**, 5331.
- 12 I. Grabchev, S. Yordanova, E. Vasileva-Tonkova, M. Cangiotti, A. Fattori, R. Alexandrova, S. Stoyanov and M. F. Ottaviani, *Dyes Pigm.*, 2016, **129**, 71.
- 13 L. G. Alves, P. F. Pinheiro, J. R. Feliciano, D. P. Dâmaso, J. H. Leitão and A. M. Martins, *Int. J. Antimicrob. Agents*, 2017, **49**, 646.
- 14 L. G. Alves, J. F. Portel, S. A. Sousa, O. Ferreira, S. Almada, E. R. Silva, A. M. Martins and J. H. Leitão, *Antibiotics*, 2019, **8**, 224.
- 15 S. Almada, L. B. Maia, J. C. Waerenborgh, B. J. C. Vieira, N. P. Mira, E. R. Silva, F. Cerqueira, E. Pinto and L. G. Alves, *New J. Chem.*, 2022, **46**, 16764.
- 16 A. V. Yadav, A. S. Shete, A. P. Dabke, P. V. Kulkarni and S. S. Sakhare, *Indian J. Pharm. Sci.*, 2009, **71**, 359.



- 17 J. B. Ngilirabanga and H. Samsodien, *Wiley Online Library*, 2021, vol. 2, p. 512.
- 18 M. B. Hickey, M. L. Peterson, L. A. Scoppettuolo, S. L. Morrisette, A. Vetter, H. Guzmán, J. F. Remenar, Z. Zhang, M. D. Tawa, S. Haley, M. J. Zaworotko and O. Almarsson, *Eur. J. Pharm. Biopharm.*, 2007, **67**, 112.
- 19 M. Djaló, A. E. S. Cunha, J. P. Luís, S. Quaresma, A. Fernandes, V. André and M. T. Duarte, *Cryst. Growth Des.*, 2021, **21**, 995.
- 20 O. Shemchuk, V. André, M. T. Duarte, D. Braga and F. Grepioni, *CrystEngComm*, 2019, **21**, 2949.
- 21 V. André, M. F. M. Piedade and M. T. Duarte, *CrystEngComm*, 2012, **14**, 5005.
- 22 E. Grothe, H. Meekes, E. Vlieg, J. H. ter Horst and R. de Gelder, *Cryst. Growth Des.*, 2016, **16**, 3237.
- 23 N. K. Evanson, *xPharm: The Comprehensive Pharmacology Reference*, Elsevier, 2007.
- 24 B. L. Furman, *Reference Module in Biomedical Sciences*, Elsevier, 2018.
- 25 G. Royal, V. Dahaoui-Gindrey, S. Dahaoui, A. Tabard, R. Guillard and C. L. Pullumbi, *Eur. J. Org. Chem.*, 1998, **9**, 1971.
- 26 L. G. Alves, M. A. Antunes, I. Matos, R. F. Munhá, M. T. Duarte, A. C. Fernandes, M. M. Marques and A. M. Martins, *Inorg. Chim. Acta*, 2010, **363**, 1823.
- 27 Bruker AXS, *SAINT⁺, release 6.22*, Bruker Analytical Systems, Madison, WI, USA, 2005.
- 28 Bruker AXS, *SADABS*, Bruker Analytical Systems, Madison, WI, USA, 2005.
- 29 G. M. Sheldrick, *Acta Crystallogr., Sect. A: Found. Adv.*, 2015, **71**, 3.
- 30 G. M. Sheldrick, *Acta Crystallogr., Sect. C: Struct. Chem.*, 2015, **71**, 3.
- 31 L. J. Farrugia, *J. Appl. Crystallogr.*, 1999, **32**, 837.
- 32 C. F. Macrae, I. Sovago, S. J. Cottrell, P. T. A. Galek, P. McCabe, E. Pidcock, M. Platings, G. P. Shields, J. S. Stevens, M. Towler and P. A. Wood, *J. Appl. Crystallogr.*, 2020, **53**, 226.
- 33 A. L. Spek, *J. Appl. Crystallogr.*, 2003, **36**, 7.
- 34 F. Siopa, T. Figueiredo, R. F. M. Frade, I. Neto, A. Meirinhos, C. P. Reis, R. G. Sobral, C. A. M. Afonso and P. Rijo, *ChemistrySelect*, 2016, **1**, 5909.
- 35 M. P. Weinstein, J. B. Patel, C.-A. Burnham, S. Campeau, P. S. Conville, C. Doern, G. M. Eliopoulos, M. F. Galas, R. M. Humphries, S. G. Jenkins, S. M. Kircher, J. S. Lewis, B. Limbago, A. J. Mathers, T. Mazzulli, S. D. Munro, M. O. S. de Danies, R. Patel, S. S. Satlin, J. M. Swenson, A. Wong, W. F. Wang and B. L. Zimmer, *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically*, Clinical and Laboratory Standards Institute, Wayne, USA, 2018.
- 36 L. G. Alves, M. T. Duarte and A. M. Martins, *J. Mol. Struct.*, 2015, **1098**, 277.
- 37 D. Lin-Vien, N. B. Colthup, W. G. Fateley and J. G. Grasselli, *The handbook of infrared and Raman characteristic frequencies of organic molecules*, Academic Press, San Diego, USA, 1991.
- 38 M. S. Fonari, E. V. Ganin, S. S. Basok, K. A. Lyssenko, M. J. Zaworotko and V. C. Kravtsov, *Cryst. Growth Des.*, 2010, **10**, 5210.

